MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Revenue
$15,034M
Net Income
-$248M
Net Profit Margin
-1.65%
EPS
-$0.04
Unit: Million (M) dollars
Revenue Breakdown
Biopharma Segment-Operating Segm...
Corporate Non Segment
Revenue Breakdown
US
International Developed Markets
International Emerging Markets
Revenue Breakdown
Revenues-Product
Alliance revenues
Revenues-Royalty
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-28
2026-03-29
2025-12-31
2025-09-28
Total revenues
15,034
14,451
17,557
16,654
Cost of sales
4,092
3,548
5,272
4,172
Selling, informational and administrative expenses
3,411
2,961
4,162
3,186
Research and development expenses
2,809
2,490
3,206
2,546
Acquired in-process research and development expenses
16
137
212
1,390
Amortization of intangible assets
1,185
1,183
1,229
1,223
Restructuring charges and certain acquisition-related costs
457
100
604
286
Other (income)/deductionsnet
-3,716
-861
-4,515
-517
Income/(gain) from continuing operations before provision/(benefit) for taxes on income/(gain)
-653
3,170
-1,643
3,334
Provision/(benefit) for taxes on income/(loss)
-407
461
-2
-216
Income/(gain) from continuing operations
-246
2,709
-1,639
3,550
Discontinued operationsnet of tax
8
-13
0
0
Net income/(gain) before allocation to noncontrolling interests
-237
2,696
-1,639
3,550
Less net income attributable to noncontrolling interests
10
8
8
9
Net income/(gain) attributable to pfizer inc. common shareholders
-248
2,687
-1,647
3,541
Basic EPS
-0.04
0.47
-0.29
0.62
Diluted EPS
-0.04
0.47
-0.288
0.62
Basic Average Shares
5,699,000,000
5,691,000,000
5,687,000,000
5,685,000,000
Diluted Average Shares
5,699,000,000
5,731,000,000
5,722,000,000
5,714,000,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
PFE Income Statement Sankey Diagram
Sankey diagram visualizing PFE income statement for the period
Net income/(gain)
attributable to pfizer inc....
-$248M
(-108.52%↓ Y/Y)
Net income/(gain)
before allocation to...
-$237M
(-108.09%↓ Y/Y)
Less net income
attributable to...
$10M
(-44.44%↓ Y/Y)
Discontinued operationsnet
of tax
$8M
(-68.00%↓ Y/Y)
Income/(gain) from continuing
operations
-$246M
(-108.47%↓ Y/Y)
Provision/(benefit) for taxes on
income/(loss)
-$407M
(-388.65%↓ Y/Y)
Biopharma
Segment-Operating Segments
$14,661M
(2.49%↑ Y/Y)
Corporate Non Segment
$373M
(7.18%↑ Y/Y)
Income/(gain) from continuing
operations before...
-$653M
(-121.45%↓ Y/Y)
Total revenues
$15,034M
(2.60%↑ Y/Y)
Cost of sales
$4,092M
(8.31%↑ Y/Y)
Other
(income)/deductionsnet
-$3,716M
(-402.84%↓ Y/Y)
Selling, informational
and administrative...
$3,411M
(-0.12%↓ Y/Y)
Research and development
expenses
$2,809M
(13.17%↑ Y/Y)
Amortization of intangible
assets
$1,185M
(-2.15%↓ Y/Y)
Restructuring charges and
certain...
$457M
(2638.89%↑ Y/Y)
Acquired in-process
research and development...
$16M
(700.00%↑ Y/Y)
Buy us a coffee
Pfizer_(2021)-svg
PFIZER INC (PFE)
Pfizer_(2021)-svg
PFIZER INC (PFE)
Show more